Acute gastroenteritis causes increased mortality and morbidity in children. Currently, treatment for this illness focuses on treating and preventing dehydration, reducing severity and duration of diarrhea, and promoting weight gain following rehydration. Gelatine tannate has anti-inflammatory and astringent characteristics which gives it protective properties. It also inhibits growth of certain bacteria in the gut. In Europe recently, it has been advertised to treat gastroenteritis. However, currently there is only little evidence to demonstrate the efficacy of gelatine tannate to treat gastroenteritis in children or adults. The objective of this trial is determine the safety and efficacy of gelatine tannate for treating acute gastroenteritis in children.
This is a randomized, placebo-controlled, blind trial. A total of 158 children younger than 5 years old were recruited for the study. Children older than 3 years old will receive 500 mg per day, and children under 3 years old will receive 350 mg per day for 5 days. If not given the drug, they were given a matching placebo. The main outcome measured was duration of diarrhea. All participants were followed up for the 5 days of the intervention, as well as an additional 48 hours. This study has not been conducted yet. I am interested to see if this study finds gelatine tannate to be a potential treatment for this condition.
Michałek D, Kołodziej M, Konarska Z, Szajewska H. Efficacy and safety of gelatine tannate for the treatment of acute gastroenteritis in children: protocol of a randomised controlled trial. BMJ Open. 2016;6(2):e010530. doi:10.1136/bmjopen-2015-010530.